Eli Lilly and Company Stock News

Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.

These two healthcare giants have impressive growth potential for different reasons. Eli Lilly is getting a lot of attention for its GLP-1 successes, and another blockbuster could be just around the corner.

These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.

Eli Lilly is the market-share leader for weight-loss drugs. Coverage by government insurance programs is a huge win for the company.

VICTORIA, Seychelles, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has announced the official addition of LLYUSDT, MAUSDT, UNHUSDT stock index perpetual futures, expanding its range of Real World Asset (RWA) products for global traders. Bitget users can access these contracts with leverage of up to 10x.

MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in milestones, and tiered royalties, strengthening its financial position and reducing near-term dilution risk. The company's riboswitch technology and multiple collaborations, including with Johnson & ...

Eli Lilly's strong price action and high ratings present a bull call spread trading opportunity with large profit potential and clearly defined risk parameters.

Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.